Dr. Robert Pawel Palusinski, MD

Dr. Palusinski practices at Mat-Su Regional Medical Center in Palmer, Alaska, part of Community Health Systems.

Dr. Palusinski's NPI, 1770750044, was assigned on May 14, 2008. Dr. Palusinski holds Colorado license DR.0058334.

Dr. Palusinski's primary practice is Mat-Su Regional Medical Center, at 2500 South Woodworth Loop, Palmer, AK 99645 in Matanuska-Susitna Borough. The practice phone is (907) 861-6000.

Dr. Palusinski's primary practice is Mat-Su Regional Medical Center in Palmer, Alaska, part of Community Health Systems. Dr. Palusinski is also affiliated with Guam Regional Medical City. The medical group on file is Guam Regional Medical City. Dmand AI also links Dr. Palusinski to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Palusinski practices, 4 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Palusinski's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Palusinski's licenses on file in 3 states: Colorado, Guam and Iowa.

CMS data shows 1,258 Medicare services from Dr. Palusinski across 14 procedure codes in 2024, for 540 Medicare patients. Medicare paid $53,162 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 540 Medicare patients who saw Dr. Palusinski in 2024. The largest group is 65 to 74, with 223 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Palusinski's median patient age at 66, with 45% women.

In 2024, Dr. Palusinski wrote 432 Medicare Part D claims for 57 patients. 83% of them were for generic drugs. CMS names the drug for 385 of them, across 12 drugs with 11 or more claims each, at $47,053 in total drug cost. In 2023, CMS named 278 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Palusinski for performance year 2024, reported as part of a group. Dr. Palusinski accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 302 general payments to Dr. Palusinski from 25 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 84% of the total. Janssen Pharmaceuticals, Inc paid the most, $725.